OVID vs. HOWL, PRLD, TSVT, GBIO, CDT, ELYM, QURE, DSGN, ALDX, and ATOS
Should you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Werewolf Therapeutics (HOWL), Prelude Therapeutics (PRLD), 2seventy bio (TSVT), Generation Bio (GBIO), Conduit Pharmaceuticals (CDT), Eliem Therapeutics (ELYM), uniQure (QURE), Design Therapeutics (DSGN), Aldeyra Therapeutics (ALDX), and Atossa Therapeutics (ATOS). These companies are all part of the "pharmaceutical preparations" industry.
Ovid Therapeutics (NASDAQ:OVID) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.
Werewolf Therapeutics has higher revenue and earnings than Ovid Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Werewolf Therapeutics had 5 more articles in the media than Ovid Therapeutics. MarketBeat recorded 9 mentions for Werewolf Therapeutics and 4 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.44 beat Werewolf Therapeutics' score of 0.42 indicating that Ovid Therapeutics is being referred to more favorably in the media.
72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 13.3% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 21.1% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Ovid Therapeutics currently has a consensus price target of $8.08, suggesting a potential upside of 165.03%. Werewolf Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 141.94%. Given Ovid Therapeutics' higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Werewolf Therapeutics.
Ovid Therapeutics received 321 more outperform votes than Werewolf Therapeutics when rated by MarketBeat users. Likewise, 70.55% of users gave Ovid Therapeutics an outperform vote while only 63.16% of users gave Werewolf Therapeutics an outperform vote.
Ovid Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.
Werewolf Therapeutics has a net margin of -256.33% compared to Ovid Therapeutics' net margin of -10,691.14%. Werewolf Therapeutics' return on equity of -36.15% beat Ovid Therapeutics' return on equity.
Summary
Ovid Therapeutics and Werewolf Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Ovid Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ovid Therapeutics Competitors List
Related Companies and Tools
